Home > News > Altair Nanotechnologies Announces New Preclinical Testing
February 5th, 2004
Altair Nanotechnologies Announces New Preclinical Testing
Altair Nanotechnologies, Inc., a developer and manufacturer of innovative nanomaterial products, announced that it is planning to conduct new preclinical testing of its drug candidate, RenaZorb. The test will use an animal model directly comparing RenaZorb with existing and proposed drugs for phosphate control in patients with End Stage Renal Disease undergoing dialysis. The testing is expected to be initiated within 30 to 45 days. The company also announced that it plans to file an IND application with the U.S. Food and Drug Administration.
University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014
Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014
QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014
Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014